Novel antipsychotics and the neuroleptic malignant syndrome: A review and critique

Samia Hasan, Peter Buckley

Research output: Contribution to journalArticle

143 Citations (Scopus)

Abstract

Objective: The authors' goal was to analyze reported cases of neuroleptic malignant syndrome in patients given clozapine and risperidone. Method: They assessed 19 cases of clozapine-induced neuroleptic malignant syndrome and 13 cases of risperidone-induced neuroleptic malignant syndrome against three criteria sets and against extent of exclusionary workup and then designated them as high or low probability of being neuroleptic malignant syndrome. Results: Nine of the 19 cases of clozapine-related neuroleptic malignant syndrome and eight of the 13 cases of risperidone- related neuroleptic malignant syndrome were designated as having high probability of being neuroleptic malignant syndrome. The remainder were designated as having low probability because presentations were not linked to treatment or failed to meet criteria for the syndrome. Conclusions: Neuroleptic malignant syndrome can occur in patients given atypical antipsychotics and resembles 'classical' neuroleptic malignant syndrome. However, side effect profiles overlap considerably with neuroleptic malignant syndrome criteria, and atypical antipsychotics may cause neurotoxicities unrelated to (but misattributed as) neuroleptic malignant syndrome. Insufficient evidence exists for 'atypical' neuroleptic malignant syndrome with novel antipsychotics.

Original languageEnglish (US)
Pages (from-to)1113-1116
Number of pages4
JournalAmerican Journal of Psychiatry
Volume155
Issue number8
DOIs
StatePublished - Jan 1 1998

Fingerprint

Neuroleptic Malignant Syndrome
Antipsychotic Agents
Risperidone
Clozapine

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Novel antipsychotics and the neuroleptic malignant syndrome : A review and critique. / Hasan, Samia; Buckley, Peter.

In: American Journal of Psychiatry, Vol. 155, No. 8, 01.01.1998, p. 1113-1116.

Research output: Contribution to journalArticle

Hasan, Samia ; Buckley, Peter. / Novel antipsychotics and the neuroleptic malignant syndrome : A review and critique. In: American Journal of Psychiatry. 1998 ; Vol. 155, No. 8. pp. 1113-1116.
@article{2311121811db4258901a1975057065fa,
title = "Novel antipsychotics and the neuroleptic malignant syndrome: A review and critique",
abstract = "Objective: The authors' goal was to analyze reported cases of neuroleptic malignant syndrome in patients given clozapine and risperidone. Method: They assessed 19 cases of clozapine-induced neuroleptic malignant syndrome and 13 cases of risperidone-induced neuroleptic malignant syndrome against three criteria sets and against extent of exclusionary workup and then designated them as high or low probability of being neuroleptic malignant syndrome. Results: Nine of the 19 cases of clozapine-related neuroleptic malignant syndrome and eight of the 13 cases of risperidone- related neuroleptic malignant syndrome were designated as having high probability of being neuroleptic malignant syndrome. The remainder were designated as having low probability because presentations were not linked to treatment or failed to meet criteria for the syndrome. Conclusions: Neuroleptic malignant syndrome can occur in patients given atypical antipsychotics and resembles 'classical' neuroleptic malignant syndrome. However, side effect profiles overlap considerably with neuroleptic malignant syndrome criteria, and atypical antipsychotics may cause neurotoxicities unrelated to (but misattributed as) neuroleptic malignant syndrome. Insufficient evidence exists for 'atypical' neuroleptic malignant syndrome with novel antipsychotics.",
author = "Samia Hasan and Peter Buckley",
year = "1998",
month = "1",
day = "1",
doi = "10.1176/ajp.155.8.1113",
language = "English (US)",
volume = "155",
pages = "1113--1116",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "8",

}

TY - JOUR

T1 - Novel antipsychotics and the neuroleptic malignant syndrome

T2 - A review and critique

AU - Hasan, Samia

AU - Buckley, Peter

PY - 1998/1/1

Y1 - 1998/1/1

N2 - Objective: The authors' goal was to analyze reported cases of neuroleptic malignant syndrome in patients given clozapine and risperidone. Method: They assessed 19 cases of clozapine-induced neuroleptic malignant syndrome and 13 cases of risperidone-induced neuroleptic malignant syndrome against three criteria sets and against extent of exclusionary workup and then designated them as high or low probability of being neuroleptic malignant syndrome. Results: Nine of the 19 cases of clozapine-related neuroleptic malignant syndrome and eight of the 13 cases of risperidone- related neuroleptic malignant syndrome were designated as having high probability of being neuroleptic malignant syndrome. The remainder were designated as having low probability because presentations were not linked to treatment or failed to meet criteria for the syndrome. Conclusions: Neuroleptic malignant syndrome can occur in patients given atypical antipsychotics and resembles 'classical' neuroleptic malignant syndrome. However, side effect profiles overlap considerably with neuroleptic malignant syndrome criteria, and atypical antipsychotics may cause neurotoxicities unrelated to (but misattributed as) neuroleptic malignant syndrome. Insufficient evidence exists for 'atypical' neuroleptic malignant syndrome with novel antipsychotics.

AB - Objective: The authors' goal was to analyze reported cases of neuroleptic malignant syndrome in patients given clozapine and risperidone. Method: They assessed 19 cases of clozapine-induced neuroleptic malignant syndrome and 13 cases of risperidone-induced neuroleptic malignant syndrome against three criteria sets and against extent of exclusionary workup and then designated them as high or low probability of being neuroleptic malignant syndrome. Results: Nine of the 19 cases of clozapine-related neuroleptic malignant syndrome and eight of the 13 cases of risperidone- related neuroleptic malignant syndrome were designated as having high probability of being neuroleptic malignant syndrome. The remainder were designated as having low probability because presentations were not linked to treatment or failed to meet criteria for the syndrome. Conclusions: Neuroleptic malignant syndrome can occur in patients given atypical antipsychotics and resembles 'classical' neuroleptic malignant syndrome. However, side effect profiles overlap considerably with neuroleptic malignant syndrome criteria, and atypical antipsychotics may cause neurotoxicities unrelated to (but misattributed as) neuroleptic malignant syndrome. Insufficient evidence exists for 'atypical' neuroleptic malignant syndrome with novel antipsychotics.

UR - http://www.scopus.com/inward/record.url?scp=0031850514&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031850514&partnerID=8YFLogxK

U2 - 10.1176/ajp.155.8.1113

DO - 10.1176/ajp.155.8.1113

M3 - Article

C2 - 9699705

AN - SCOPUS:0031850514

VL - 155

SP - 1113

EP - 1116

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 8

ER -